286961-15-7

Basic information

• Product Name: 4-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)-3,6-DIHYDRO-2H-PYRIDINE-1-CARBOXYLIC ACID BENZYL ESTER
• Synonyms: 4-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)-3,6-DIHYDRO-2H-PYRIDINE-1-CARBOXYLIC ACID BENZYL ESTER;benzyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate;N-Cbz-3,6-Dihydro-2H-pyridine-4-boronic acid pinacol ester;N-Cbz-1,2,3,6-tetrahydropyridine-4-boronic acid, pinacol ester;1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-, phenylMethyl ester;benzyl 4-(tetraMethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,6-tetrahydropyridine-1-carboxylate;benzyl 5,6-dihydro-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)pyridine-1(2H)-carboxylate;1-Benzyloxycarbonyl-1,2,3,6-tetrahydropyridine-4-boronic acid pinacol ester, 98%
• CAS NO: 286961-15-7
• Molecular Formula: C₁₉H₂₆BNO₄
• Molecular Weight: 343.23
• Mol File: 286961-15-7.mol
• Article Data: 13

Chemical Properties

• Melting Point: 88-90℃
• Boiling Point: 418.2 °C at 760 mmHg
• Flash Point: 206.7 °C
• Appearance: Off-white/Solid
• Density: 1.13
• Vapor Pressure: 3.35E-07mmHg at 25°C
• Refractive Index: 1.541
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• PKA: -1.26±0.40(Predicted)
• CAS DataBase Reference: 4-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)-3,6-DIHYDRO-2H-PYRIDINE-1-CARBOXYLIC ACID BENZYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)-3,6-DIHYDRO-2H-PYRIDINE-1-CARBOXYLIC ACID BENZYL ESTER(286961-15-7)
• EPA Substance Registry System: 4-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)-3,6-DIHYDRO-2H-PYRIDINE-1-CARBOXYLIC ACID BENZYL ESTER(286961-15-7)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-37
• TSCA: No
• Hazardous Substances Data: 286961-15-7(Hazardous Substances Data)

Usage

Uses

Benzyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate is a reactant used in the synthesis of potent and orally bioavailable inhibitors of βII tryptase used in the treatment of allergic diseases.

InChI:InChI=1/C19H26BNO4/c1-18(2)19(3,4)25-20(24-18)16-10-12-21(13-11-16)17(22)23-14-15-8-6-5-7-9-15/h5-10H,11-14H2,1-4H3

Upstream product

• 1195-66-0 2-methoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 73183-34-3 bis(pinacol)diborane 
• 1121057-75-7 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,6-tetrahydropyridine hydrochloride 
• 501-53-1 benzyl chloroformate 
• 19099-93-5 benzyl 4-oxo-1-piperidinecarboxylate 
• 286961-24-8 benzyl 1,2,3,6-tetrahydro-4-(trifluoromethylsulphonyloxy)-pyridine-1-carboxylate 

Downstream Products

• 161609-91-2 benzyl 4-phenyl-3,6-dihydropyridine-1(2H)-carboxylate 
• 286961-23-7 benzyl 4-(4-methoxyphenyl)-3,6-dihydropyridine-1(2H)-carboxylate 
• 630116-80-2 3-cyano-3',6'-dihydro-2'H-[2,4']bipyridinyl-1'-carboxylic acid benzyl ester 
• 1251537-33-3 (1-((benzyloxy)carbonyl)-1,2,3,6-tetrahydropyridin-4-yl)boronic acid 
• 70684-85-4 N-[(benzyloxy)carbonyl]-1,2,3,6-tetrahydropyridine-4-carboxylic acid 

Relevant articles and documents

Technological method for synthesizing N-substituted-1,2,5,6-tetrahydropyridine-4-boric acid ester

The invention relates to an organic compound synthesis method, in particular to a technological method for synthesizing N-substituted-1,2,5,6-tetrahydropyridine-4-boric acid ester. The method comprises the step that N-substituted-1,2,5,6-tetrahydropyridine-4-halide serves as a raw material to react with bi-boric acid ester, cuprous halide or cuprous oxide, a ligand and organic base in a solvent, so that N-substituted-1,2,5,6-tetrahydropyridine-4-boric acid ester is obtained. The method is innovative, and easy and convenient to operate, the technological route is short, the cost is low, the product purity is high, the reaction conditions are mild, the situation that metal palladium coupling or a high-activity Grignard reagent and a low temperature condition are adopted in a traditional method is avoided, and the method has potential cost advantage, and is suitable for industrialized scale-up production.

INHIBITORS OF FATTY ACID AMIDE HYDROLASE

Provided herein are compounds of formula (I): or pharmaceutically acceptable salts, solvates or prodrugs thereof or mixtures thereof, wherein Z1, Z2, X1, X2, X3, R1, R2 R3/

SMALL MOLECULE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASES (PRMTS)

The present invention relates to compounds that are useful as inhibitors of protein arginine methyltransferase that have a formula selected from Formula (I), Formula (II) and Formula (III), as well as racemic mixtures, diastereomers, enantiomers and tautomers thereof and N-oxides, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof as defined herein. Said compound are useful as inhibitors of PRMTs and/or CARM-I. The invention further relates to compositions comprising such compounds and methods for their use.